In conclusion, we propose that the CFH Tyr402His polymorphism does not influence the plasma levels of CFH protein in patients with AMD or in the control group of normal individuals and that this polymorphism does not appear to be related to changes in the serum levels of other components of the alternative pathway of complement. Here, CFH is linked to age-related macular degeneration.